RECRUITINGINTERVENTIONAL

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD)

About This Trial

IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.

Who May Be Eligible (Plain English)

Screening Program- Who May Qualify: - Adults with type 2 diabetes (T2D) - Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP). - Lack of estimated glomerular filtration rate (eGFR) and/or urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR Who Should NOT Join This Trial: • Chronic kidney disease (CKD) diagnosis Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Screening Program- Inclusion Criteria: * Adults with type 2 diabetes (T2D) * Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP). * Lack of estimated glomerular filtration rate (eGFR) and/or urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR Exclusion Criteria: • Chronic kidney disease (CKD) diagnosis

Treatments Being Tested

OTHER

(IRIS-CKD Screening Program): Home Kit

All participants approached for enrollment in Program 1 will receive National Kidney Foundational educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab(s) results. Home Test Kit: a kit delivered to participants homes with instructions to complete eGFR (fingerstick) and/or UACR (urine sample) testing, depending on which lab(s) are missing at baseline.

OTHER

(IRIS-CKD Screening Program): Standard Lab Order

ll participants approached for enrollment in Program 1 will receive National Kidney Foundation educational materials related to CKD screening in type 2 diabetes and study information. All enrolled participants will receive a message regarding study lab

Locations (6)

University of Alabama

Birmingham, Alabama, United States

Orlando Health

St. Petersburg, Florida, United States

University of Michigan

Ann Arbor, Michigan, United States

Essentia Health

Duluth, Minnesota, United States

Duke University

Durham, North Carolina, United States

Baylor Scott & White

Temple, Texas, United States